New Pill for People with Type 2 Diabetes
This press release is an announcement submitted by Upjohn Company, and was not written by Diabetes Health.
The Glynase PresTab tablet is a patented 3 mg glyburide tablet that divides easily in two with the press of a finger. This new design allows diabetes patients to measure their prescribed daily dosage easily and accurately, with a consistent available potency between 90% and 100%.
According to the Upjohn Company, Glynase PresTab's improved potency allows patients to take a dosage lower than the already available Micronase glyburide tablet and still expect the same results. The Upjohn Company recommends that patients have their dosage readjusted by a doctor before switching from Micronase or other hypoglycemic agents to Glynase PresTab.Click Here To View Or Post Comments